T-Therapeutics reloads with a $133M megaround for bispecifics

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 05 Nov, 12:52 UTC

The startup is built around technology it claims can help get after known, but undruggable cancer targets and design particularly selective autoimmune disease treatments.

science

Sources

• T2T-Therapeutics reloads with a $133M megaround for bispecificsBioPharma Dive / Healthcare Dive / MedTech Dive05 Nov, 12:52